Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A 40-year-old male known for gout presented to the emergency department with a 3-day history of fever, shortness of breath, non-productive cough, nausea, and vomiting. On presentation, the patient was febrile to 38.4°C, with a pulse of 109, and oxygen saturation of 97% on room air. His physical exam revealed diffuse bilateral crackles.

Complete blood count was unremarkable, and lactate dehydrogenase (LDH) was mildly increased to 264 U/L (reference range 135-225). Other laboratory values were within normal limits including basic metabolic panel, lactate, liver enzymes and lipase. The chest x-ray demonstrated multifocal pneumonia, and chest CT showed bibasilar and right upper lobe ground glass opacities (Fig. 1).

Real-time reverse transcription polymerase chain reaction (rRT-PCR) testing of a nasopharyngeal swab specimen by the Xpert Xpress SARS-CoV-2 Assay (Cepheid; Sunnyvale, CA) was negative. Testing for routine respiratory viruses was also performed by the Xpert Flu/RSV Assay (Cepheid) and the ePlex Respiratory Pathogen Panel (GenMark Diagnostics; Carlsbad, CA), and were negative. Blood cultures showed no growth at five days.

The patient received treatment with ceftriaxone, azithromycin, and oxygen support (1−2 L/min). Given the radiologic findings and persistent clinical suspicion for coronavirus disease 2019 (COVID-19), repeat nasopharyngeal swab testing for SARS-CoV-2 using the Stanford Emergency Use Authorization (EUA) laboratory-developed test was performed and was negative (U.S. Food and Drug Administration, 2020). Bronchoscopy was considered but deferred due to the infection control risk. A laboratory-developed ELISA targeting the SARS-CoV-2 spike protein receptor binding domain (RBD) at day four of hospitalization showed a borderline IgM positive result at an optical density of 0.45 (negative; reference range <0.4), and IgG negative at 0.23 (negative; reference range <0.3) (Roltgen et al., 2020).

The patient was discharged home eight days following admission. The working diagnosis was that of SARS-CoV-2 pneumonia; no antiviral therapy was administered as he was considered ineligible due to a lack of positive nucleic acid amplification testing. Four months after initial presentation, he has not had medical follow-up at our center.

Retrospective rRT-PCR and serologic testing of residual plasma specimens was performed to confirm the diagnosis of COVID-19. SARS-CoV-2 RNA was detected from plasma samples drawn on days 4 and 5 of admission. The day 4 specimen was drawn the same day as the IgM-positive specimen, and was positive by rRT-PCR targeting the E gene at a cycle threshold (Ct) of 37.3, and by rRT-PCR targeting the N2 region of the nucleoprotein (N) gene at a Ct of 34.0 (Bulterys et al., 2020). The plasma specimen from the following day was positive only by the N2 rRT-PCR at a Ct of 36.3. Plasma specimens drawn 6 and 7 days following initial presentation were E and N2 rRT-PCR negative; however serologic testing of these specimens was negative.
confirmed SARS-CoV-2 IgA and IgG seroconversion against RBD, the S1 region of the spike protein, and the nucleocapsid protein (Hanson et al., 2020, Roltgen et al., 2020).

Upper respiratory sampling is the most common means to confirm the diagnosis of acute COVID-19 infection, and performs adequately in most cases. However, this clinical case illustrates the important challenge of confirming an acute diagnosis of COVID-19 infection in the presence of repeatedly negative rRT-PCR testing of upper respiratory tract specimens and an isolated, weak-positive IgM. Despite the high analytical sensitivity of nucleic acid amplification testing, decreased clinical sensitivity of upper tract specimens may be observed in COVID-19 patients presenting with pneumonia (Parikh et al., 2020, Winichakoon et al., 2020, Woloshin et al., 2020). When clinical suspicion persists despite negative nucleic acid results from upper respiratory tract samples, lower tract sampling by bronchoscopy may be considered. However, this aerosol-generating

Fig. 1. (A) Chest x-ray on admission revealed multifocal pneumonia. (B) Chest CT scan on day 1 of admission revealed bibasilar and right upper lobe ground glass opacities.
procedure is often deferred, due to its attendant transmission risks to healthcare workers.

Importantly, this case provides evidence that plasma may serve as a lower-risk, diagnostic alternative to bronchoalveolar lavage fluid, specifically when upper respiratory tract testing is negative, and imaging is consistent with viral pneumonia. Recent work from several groups has demonstrated that plasma SARS-CoV-2 RNA is a marker for COVID-19 severity (Hogan et al., 2020, Pinsky and Hogan, 2020, Prebensen et al., 2020), indicating that this plasma approach may be particularly effective in identifying patients that have developed lower tract disease.

Plasma SARS-CoV-2 RNA testing requires that the laboratory perform a separate validation for this specimen type, which requires additional time and resources. However, given that plasma is a commonly used matrix for virology molecular testing, current routine processes are well suited to address this specimen type. For institutions where plasma is not validated as a specimen type, testing may be considered at the discretion of the medical director, and results may be issued with a disclaimer that the specimen type is nonvalidated. Furthermore, laboratory staff must be aware of validated specimen types to avoid unnecessary test request rejection. Clinical laboratories must have an on-call physician to address these issues on an ad hoc basis, if no policy is explicitly in place for routine receipt of these specimen types.

In summary, the diagnosis of acute COVID-19 relies primarily on nucleic acid amplification testing of upper respiratory specimens. However, lower respiratory tract and plasma SARS-CoV-2 nucleic acid amplification testing may also be considered; and the latter may be of particular utility in cases where bronchoscopy is deferred due to clinical factors or transmission risk. Confirmation of SARS-CoV-2 infection is paramount to prevent lapses in infection control, and to enable timely initiation of therapy when indicated.

Funding

None.

Declaration of competing interest

The authors report no conflicts of interest relevant to this article.

Acknowledgments

We would like to thank the staff of the Stanford Health Care Clinical Virology Laboratory for their high-quality work and dedication to patient care.

References

Bultery PL, Garamani N, Stevens B, Sahoo MK, Huang C, Hogan CA, et al. Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2. J Clin Virol 2020;129: 104427.

Hanson KE, Caliendo AM, Arias CA, Englund JA, Hayden MK, Lee MJ, et al. Infectious Diseases Society of America guidelines on the diagnosis of Coronavirus Disease 2019 (COVID-19): Serologic Testing. Clin Infect Dis 2020;ciaa1343.

Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, et al. High frequency of SARS-CoV-2 RNAemia and association with severe disease. Clin Infect Dis 2020;ciaa1054.

Parikh BA, Bailey TC, Lyons PG, Anderson NW. The brief case: “not positive” or “not sure”—COVID-19-negative results in a symptomatic patient. J Clin Microbiol 2020;58(8) e01195-20.

Pinsky BA, Hogan CA. Carving out a niche for SARS-CoV-2 plasma RNA testing. Clin Infect Dis 2020.

Prebensen C, Hre PLM, Jonassen C, Rangberg A, Blomfeldt A, Svensson M, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. Clin Infect Dis 2020.

Roltgen K, Wirz OF, Stevens BA, Powell AE, Hogan CA, Najeeb J, et al. SARS-CoV-2 antibody responses correlate with resolution of RNAemia but are short-lived in patients with mild illness. medRxiv 2020.

U.S. Food and Drug Administration. Stanford Health Care Clinical Virology Laboratory SARS-CoV-2 test EUA Summary. Available from: https://www.fda.gov/media/136818/download. Accessed October 2, 2020.

Winchukoon P, Chaiwarith R, Liverisssakut C, Salee P, Goonna A, Limsumuk A, et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19. J Clin Microbiol 2020;58(5).

Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection - challenges and implications. N Engl J Med 2020;383(6):e38.